MirMDD is an AI-driven precision transcriptomics platform. Designed for longitudinal monitoring, it transforms complex biological signals into early, objective decisions for clinical trials in psychiatric disorders and other complex therapeutic areas.
We select our biological signatures based on the most rigorous scientific knowledge, combining the analysis of existing evidence with advanced in-house discovery capabilities.
We have built a proprietary database derived from an exhaustive systematic review of global literature. This tool allows us to identify highly consistent biomarkers for psychiatric pathologies, with full scalability to be applied to other complex clinical areas.
Moving beyond bibliography, we implement an active discovery phase. We analyze all data obtained from massive sequencing (RNA-seq) in our cohorts to find new specific transcriptional markers and emerging biological pathways.
MirMDD is a research-stage transcriptomics platform designed to measure molecular change during neuropsychiatric drug development, support biomarker-driven trials and uncover new opportunities for compounds with mixed clinical results.
The circulating transcriptome reflects the communication between the nervous, immune, and endocrine systems. We analyze various classes of molecules in a complementary manner:
Reflects coding gene expression in key dynamic pathways such as stress response (FKBP5, glucocorticoid receptors), neuroplasticity (BDNF), and immunoinflammation (interferon and cytokines).
Powerful post-transcriptional regulators highly stable in circulation. They coordinate complex networks of neurogenesis, neurotransmitter response, and intracellular signaling.
Covalently closed structures with exceptional resistance to exonuclease degradation. An excellent substrate for stable, long-term monitoring panels (e.g., CDR1as, HIPK2).
Long-chain non-coding RNA that acts in epigenetic and chromatin regulation, providing an additional layer of information on clinical subphenotypes.
At MirMDD, we are shifting the paradigm. To overcome the immense interindividual variability that has historically hindered the development of blood biomarkers, we focus exclusively on trajectory analysis.
By capturing the patient's baseline state, they become their own biological control, mathematically canceling static confounding variables (genetics, age, lifestyle).
We monitor evolution across critical pharmacodynamic milestones. We measure the rate and direction of transcriptomic change induced exclusively by the drug.
The result is a pure pharmacodynamic signal. This drastically reduces required sample sizes and detects biological efficacy weeks before subjective questionnaires.
Clinical symptom scores describe patient outcomes. Longitudinal RNA measurements add a complementary view of biological response and help generate testable hypotheses about treatment mechanisms.
Explore transcriptomic signatures linked to inflammation, stress signalling, cellular regulation and treatment-associated change.
Compare within-patient molecular profiles across planned visits, including early follow-up windows.
Combine molecular trajectories with clinical endpoints to refine biomarker hypotheses and prospective trial designs.
Human biology is inherently complex. A single isolated biomarker rarely provides the predictive power necessary for making critical decisions in drug development.
MirMDD incorporates proprietary bioinformatic pipelines based on Machine Learning and Artificial Intelligence. Our models integrate multiple transcriptional signals, assigning and dynamically adjusting the relative weights of each molecule into a consolidated multivariable index.
Automated variable selection to eliminate redundancy without losing critical biological information.
Continuous calculation of the mathematical distance between the patient's trajectory and healthy reference profiles.
Cross-validation through k-fold resamplings and strict parameter freezing prior to clinical unblinding.
Standardized processing by RNA class
Intra-individual relative difference vs Baseline
Adjustment by predetermined direction
Unified quantitative response index
Integrate MirMDD into your clinical trials to accelerate decision-making. Modular solutions designed to mitigate risk at every stage of development.
Early identification of Responders vs Non-Responders during the first weeks of treatment (Day 7–15). Avoid waiting 8 weeks of trial to objectify target engagement and biological efficacy.
Objective stratification of trial populations based on transcriptomic signatures (e.g., subgroups with high neuroinflammation, HPA dysfunction or metabolic deficit). Ensure your drug is tested in the right population.
Continuous and objective monitoring of the patient's trajectory toward biological remission. Detect underlying molecular alterations before clinical relapses manifest.
Identification of predictive pre-treatment signatures for the strategic positioning of your compound against standard of care or competitors. The foundation for your future Companion Diagnostic (CDx).
A clinical trial can miss its primary endpoint while leaving valuable biological signals in the data. MirMDD is designed to help biopharma teams reassess discontinued or underperforming CNS assets, investigate response heterogeneity and build biomarker-informed hypotheses for a new development pathway.
Reassess trial endpoints, dosing, timing, clinical subgroups and available biospecimens.
Study longitudinal transcriptomic patterns and pathways associated with exposure and clinical change.
Investigate biological heterogeneity and predefine response-enrichment hypotheses.
Propose a focused study with prespecified biomarker, pharmacodynamic and clinical endpoints.
* Drug rescue is an exploratory R&D strategy. Clinical benefit, predictive performance and successful asset revival require independent prospective validation.
Explore an R&D partnership for pharmacodynamic biomarkers, biomarker-driven trial design or CNS drug rescue.